Sir Julian Lewis: I believe many children were treated with puberty blockers, among other drugs, before the Gender Identity Development Service programme was closed down. Does the hon. Member know what has happened to all the data from those children who were previously treated, or why it should be necessary to treat any more children with these drugs until enough time has elapsed to enable that data, and the treatment’s consequences, to be verified?

[Jamie Stone: What I am about to say relates to the right hon. Member’s intervention. It is not unusual in medicine for children to participate in clinical trials, provided that there are robust safeguards, clear parental consent and proper oversight. But can a distressed teenager and a family desperate to help truly grasp these long-term implications? The legal experts I consulted spoke about the delicate ethics at play. Medical research always involves balancing competing risks: the risks of harm from an intervention versus the risks of harm from withholding it. …]